| 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone | Not Available |
| Geldanamycin | Not Available |
| PD173955 | Not Available |
| Radicicol | Not Available |
| Nilotinib | A kinase inhibitor used for the chronic phase treatment of Chronic Myeloid Leukemia (CML) that is Philadelphia chromosome positive and for the treatment of CML that is resistant to therapy containing imatinib. |
| Tandutinib | Investigated for use/treatment in leukemia (myeloid). |
| Piceatannol | Not Available |
| Flumatinib | Flumatinib has been used in trials studying the treatment of Myelogenous Leukemia, Chronic. |
| Genistein | Currently Genistein is being studied in clinical trials as a treatment for prostate cancer. |
| Imatinib | A tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. |
| Sunitinib | A receptor tyrosine kinase inhibitor and chemotherapeutic agent used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). |
| Gefitinib | A tyrosine kinase inhibitor used as first-line therapy to treat non-small cell lung carcinoma (NSCLC) that meets certain genetic mutation criteria. |
| Erlotinib | An EGFR tyrosine kinase inhibitor used to treat certain small cell lung cancers or advanced metastatic pancreatic cancers. |
| Vemurafenib | A kinase inhibitor used to treat patients with Erdheim-Chester Disease who have the BRAF V600 mutation, and melanoma in patients who have the BRAF V600E mutation. |
| Sorafenib | A kinase inhibitor used in the treatment of unresectable liver carcinoma and advanced renal carcinoma. |
| Pazopanib | An antineoplastic agent used in the treatment of advanced renal cell cancer and advanced soft tissue sarcoma in patients with prior chemotherapy. |
| Lapatinib | An antineoplastic agent and tyrosine kinase inhibitor used for the treatment of advanced or metastatic HER-negative breast cancer in patients who received prior chemotherapeutic treatments. |
| Motesanib | Investigated for use/treatment in solid tumors. |
| Cabozantinib | A tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. |
| Axitinib | An oral VEGFR and kinase inhibitor used for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. |
| Dasatinib | A tyrosine kinase inhibitor used for the treatment of lymphoblastic or chronic myeloid leukemia with resistance or intolerance to prior therapy. |
| Selumetinib | A MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). |
| Ibrutinib | An antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. |
| Vandetanib | An antineoplastic kinase inhibitor used to treat symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. |
| Bosutinib | An antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. |
| Nintedanib | A triple angiokinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and in combination with docetaxel for non-small cell lung cancer. |
| Fostamatinib | A spleen tyrosine kinase inhibitor used to treat chronic immune thrombocytopenia after attempting one other treatment. |
| Acalabrutinib | A Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. |
| Ponatinib | A kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML). |
| Afatinib | An antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy. |
| Cediranib | For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors. |
| Dovitinib | Investigated for use/treatment in multiple myeloma and solid tumors. |
| Lenvatinib | A receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma. |
| Ruxolitinib | A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. |
| Pacritinib | Pacritinib is under investigation for the prevention of Acute Myeloid Leukemia (AML). |
| Crizotinib | A receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive. |
| Lestaurtinib | Investigated for use/treatment in pancreatic cancer, prostate cancer, and leukemia (myeloid). |
| Saracatinib | Saracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer. |
| Alectinib | A kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
| Brigatinib | An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
| Ceritinib | An antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib. |
| Midostaurin | An antineoplastic agent used to treat high-risk acute myeloid leukemia (AML) with specific mutations, aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL). |
| Neratinib | A protein kinase inhibitor used to treat breast cancer that over expresses the HER2 receptor. |
| Osimertinib | A tyrosine kinase inhibitor used in the treatment of certain types of non-small cell lung carcinoma. |
| Regorafenib | A kinase inhibitor used to treat patients with metastatic colorectal cancer, unresectable, locally advanced, or metastatic gastrointestinal stromal tumors, and hepatocellular carcinoma. |
| Canertinib | Investigated for use/treatment in breast cancer and lung cancer. |
| Crenolanib | Crenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma. |
| Entrectinib | Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults. Entrectinib is also indicated in adults and children over 12 years old for the treatment... |
| Foretinib | Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally... |
| Glesatinib | Investigated for use/treatment in cancer/tumors (unspecified). |
| Icotinib | Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy. |
| Radotinib | Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such... |
| Savolitinib | Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others. |
| Tesevatinib | Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.
Tesevatinib is a potent inhibitor of multiple RTKs... |
| Vatalanib | Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC). |
| Dacomitinib | A medication used to treat non small cell lung cancer with EGFR exon 19 deletion of exon 21 L858R substitution. |
| Larotrectinib | A kinase inhibitor used to treat solid tumors with neurotrophic receptor tyrosine kinase gene fusion, are metastatic, high risk for surgery, or have no alternative treatments. |
| Gilteritinib | An AXL receptor tyrosine kinase inhibitor used to treat relapsed or refractory acute myeloid leukemia. |
| Erdafitinib | A fibroblast growth factor receptor tyrosine kinase inhibitor used to treat locally advanced or metastatic urothelial carcinoma. |
| Pexidartinib | An antitumor agent that is used for the treatment of rare disease tenosynovial giant cell tumors (TGCT) by inhibiting colony-stimulating factor 1 and its receptor. |
| Fedratinib | Fedratinib is indicated to treat adults with primary or secondary myelofibrosis that is either intermediate-2 or high risk. |
| Tucatinib | A kinase inhibitor used to treat certain types of unresectable/metastatic HER-2 positive breast cancer. |
| Capmatinib | A kinase inhibitor targeting c-Met receptor tyrosine kinase in the treatment of non-small cell lung cancer with MET exon 14 skipping. |
| Selpercatinib | A RET receptor tyrosine kinase inhibitor for the treatment of RET-driven non-small cell lung cancer, medullary thyroid cancer, and thyroid cancer in appropriate patient populations. |
| Tirbanibulin | A tyrosine kinase and tubulin inhibitor used to treat actinic keratosis on the face or scalp. |
| Tepotinib | An oral tyrosine kinase inhibitor targeted against MET for the treatment of metastatic non-small cell lung cancer in patients exhibiting MET exon 14 skipping mutations. |